Ten years of HPV vaccines: State of art and controversies.

Abstract

The human papillomavirus (HPV) represents one of the most common sexually transmitted infections and it has been related to cervical cancer. The HPV vaccines prevent infection with certain species of HPV associated with the development of cervical cancer or genital warts. We carried out a PubMed search up to 2015 evaluating all randomized studies published in literature. This review discusses the current status of HPVs vaccines on the global market, efficacy, safety profiles, controversies and future vaccine developments. Three HPVs vaccines are currently on the global market: bivalent, quadrivalent and ninevalent. Bivalent and quadrivalent vaccines can protect against almost 70% of cervical HPV-related cancerous and precancerous conditions and the ninevalent vaccine, instead, provides a protection against almost 90%. The use of vaccinations raised several controversies in the last years and, currently, is not possible to establish which type of vaccine is most effective, however all of them are safe.

• Authors: Roberto Angioli, Salvatore Lopez, Alessia Aloisi, Corrado Terranova, Carlo De Cicco, Giuseppe Scaletta, Stella Capriglione, Andrea Miranda, Daniela Luvero, Roberto Ricciardi, Roberto Montera, Francesco Plotti
• Journal: Critical reviews in oncology/hematology (Crit Rev Oncol Hematol) Vol. 102 Pg. 65-72 (Jun 2016) ISSN: 1879-0461 [Electronic] Netherlands
• PMID: 27066937 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Chemical References

• Papillomavirus Vaccines

Topics

• Female
• Humans
• Papillomavirus Infections (complications, prevention & control)
• Papillomavirus Vaccines (adverse effects, therapeutic use)
• Precancerous Conditions
• Uterine Cervical Neoplasms (prevention & control, virology)